Australia's TGA To Publish Details Of New Drug Applications
More Transparency To Address Stakeholder ‘Frustration’
Executive Summary
A lack of information on innovative new drug filings and issues with late notification of generic and biosimilar drug applications have led the Australian authorities to introduce some new rules starting next year.